Alamar Biosciences
Powering Precision Proteomics
Fremont · Founded 2018 · $258.0M raised
- Headquarters
- Fremont
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- alamarbio.com
- Total Funding
- $258.0M
- Last Round
- $50.0M Convertible NoteJan 2026
- Rounds
- 4
About
Alamar Biosciences, Inc. is a life science tools company founded in 2018 and headquartered in Fremont, California. The company develops and commercializes the NULISA platform — a next-generation proteomics technology enabling ultra-high sensitivity protein quantification at scale. Alamar's solutions are used in biomarker discovery, early disease detection (including cancer and neurodegenerative diseases), and pharmaceutical research. The company has raised over $170M and serves academic research centers and biopharma customers globally.
Summary
Alamar Biosciences is a Biotech company based in Fremont, founded in 2018. It has raised $258.0M in total across 4 rounds, most recently a $50.0M Convertible Note round in Jan 2026. Investors include Sands Capital, Sherpa Healthcare Partners and Qiming VP.
Tech & App Stack
7 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2026
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...